Last reviewed · How we verify
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Details
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | RECRUITING |
| Enrolment | 90 |
| Start date | Wed Jan 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jul 27 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- HIV-1-infection
Interventions
- Once daily CAB tablet + RPV tablet
- Long acting CAB injectable + long acting RPV injectable
- Long acting CAB injectable + long acting RPV injectable
Countries
South Africa, Botswana, Thailand, United States, Brazil